These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 10528039)

  • 1. Signaling pathways for cardiac hypertrophy and failure.
    Hunter JJ; Chien KR
    N Engl J Med; 1999 Oct; 341(17):1276-83. PubMed ID: 10528039
    [No Abstract]   [Full Text] [Related]  

  • 2. Adrenergic neurohumors in the heart of hamsters with hereditary myopathy during cardiac hypertrophy and failure.
    Angelakos ET; Carballo LC; Daniels JB; King MP; Bajusz E
    Recent Adv Stud Cardiac Struct Metab; 1972; 1():262-78. PubMed ID: 4283440
    [No Abstract]   [Full Text] [Related]  

  • 3. [Molecular biology and cardiology. Molecular mechanisms in heart failure].
    Sheikh SP; Carisen J; Hansen PR; Haunsø S
    Ugeskr Laeger; 1997 Apr; 159(17):2523-8. PubMed ID: 9182379
    [No Abstract]   [Full Text] [Related]  

  • 4. Activation of Na+/H+ exchanger 1 is sufficient to generate Ca2+ signals that induce cardiac hypertrophy and heart failure.
    Nakamura TY; Iwata Y; Arai Y; Komamura K; Wakabayashi S
    Circ Res; 2008 Oct; 103(8):891-9. PubMed ID: 18776042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered beta-adrenergic receptor gene regulation and signaling in chronic heart failure.
    Port JD; Bristow MR
    J Mol Cell Cardiol; 2001 May; 33(5):887-905. PubMed ID: 11343413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myocyte adrenoceptor signaling pathways.
    Xiang Y; Kobilka BK
    Science; 2003 Jun; 300(5625):1530-2. PubMed ID: 12791980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Involvement of NADPH oxidases in cardiac remodelling and heart failure.
    Sirker A; Zhang M; Murdoch C; Shah AM
    Am J Nephrol; 2007; 27(6):649-60. PubMed ID: 17901689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beta-adrenergic receptor desensitization in cardiac hypertrophy and heart failure.
    Choi DJ; Rockman HA
    Cell Biochem Biophys; 1999; 31(3):321-9. PubMed ID: 10736754
    [No Abstract]   [Full Text] [Related]  

  • 9. Transcriptional pathways and potential therapeutic targets in the regulation of Ncx1 expression in cardiac hypertrophy and failure.
    Menick DR; Li MS; Chernysh O; Renaud L; Kimbrough D; Kasiganesan H; Mani SK
    Adv Exp Med Biol; 2013; 961():125-35. PubMed ID: 23224875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Molecular biology in cardiology. Changes in the phenotype in heart failure and myocardial hypertrophy].
    Böhm M; Wankerl M; Erdmann E
    Internist (Berl); 1994 Feb; 35(2):147-54. PubMed ID: 8150580
    [No Abstract]   [Full Text] [Related]  

  • 11. Differences between pathological and physiological cardiac hypertrophy: novel therapeutic strategies to treat heart failure.
    McMullen JR; Jennings GL
    Clin Exp Pharmacol Physiol; 2007 Apr; 34(4):255-62. PubMed ID: 17324134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic factors in cardiac hypertrophy.
    Dorn GW; Hahn HS
    Ann N Y Acad Sci; 2004 May; 1015():225-37. PubMed ID: 15201163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transgenic mice with cardiac-specific over-expression of MLK7 have increased mortality when exposed to chronic beta-adrenergic stimulation.
    Christe M; Jin N; Wang X; Gould KE; Iversen PW; Yu X; Lorenz JN; Kadambi V; Zuckerman SH; Bloem LJ
    J Mol Cell Cardiol; 2004 Sep; 37(3):705-15. PubMed ID: 15350844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subcellular remodelling may induce cardiac dysfunction in congestive heart failure.
    Dhalla NS; Saini-Chohan HK; Rodriguez-Leyva D; Elimban V; Dent MR; Tappia PS
    Cardiovasc Res; 2009 Feb; 81(3):429-38. PubMed ID: 18852252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Biochemical problems in cardiac hypertrophy and chronic insufficiency].
    Swynghedauw B
    Nouv Presse Med; 1979 Oct; 8(38):3021-4. PubMed ID: 160541
    [No Abstract]   [Full Text] [Related]  

  • 16. Inducible cAMP early repressor (ICER) is a negative-feedback regulator of cardiac hypertrophy and an important mediator of cardiac myocyte apoptosis in response to beta-adrenergic receptor stimulation.
    Tomita H; Nazmy M; Kajimoto K; Yehia G; Molina CA; Sadoshima J
    Circ Res; 2003 Jul; 93(1):12-22. PubMed ID: 12791704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Transcriptional signal pathway for cardiac hypertrophy is discovered. New base for new drugs against heart failure?].
    Sylvén C
    Lakartidningen; 1998 Nov; 95(46):5189-90. PubMed ID: 9842192
    [No Abstract]   [Full Text] [Related]  

  • 18. Molecular biology of myocardial hypertrophy and failure: gene expression and trophic signaling.
    Parker TG
    New Horiz; 1995 May; 3(2):288-300. PubMed ID: 7583170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Signal transduction mechanisms controlling cardiac contractility and their alterations in chronic heart failure.
    Brodde OE; Michel MC; Zerkowski HR
    Cardiovasc Res; 1995 Oct; 30(4):570-84. PubMed ID: 8575005
    [No Abstract]   [Full Text] [Related]  

  • 20. NADPH oxidase-dependent redox signalling in cardiac hypertrophy, remodelling and failure.
    Murdoch CE; Zhang M; Cave AC; Shah AM
    Cardiovasc Res; 2006 Jul; 71(2):208-15. PubMed ID: 16631149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.